Day: March 28, 2024

HEALWELL AI achieved annual revenue from continuing operations of $7.32 million in fiscal 2023. HEALWELL ended 2023 with a strong balance sheet, having secured approximately $29.5 million from convertible debt and equity financings. Since its relaunch in Q4 2023, the Company’s annual revenue run rate has more than doubled to over $20M with the largest component of revenues now coming from SaaS and services. Management provides a positive outlook based on strong and active acquisition and business development pipeline with the potential to more than double HEALWELL’s yearly revenue run-rate to over $40 million using the Company’s existing cash on hand. HEALWELL’s strategic alliance with equity investor WELL Health Technologies Inc. continues to flourish with significant activity in both Canada and the United States. In Canada, WELL Health...

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. Fourth Quarter and Recent HighlightsThe pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies (PMM) did not meet its primary efficacy or secondary efficacy endpoints The Company implemented cost savings initiatives, including suspension of all mavodelpar development activities and a total workforce reduction of approximately 90% The Company retained an independent financial advisor to initiate a formal process to evaluate potential...

Shimmick realized significant progress with 24% growth in Shimmick Projects, with gross margin of 7% IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Shimmick Corp. (NASDAQ: SHIM), a leading water infrastructure company, today announced financial results for the fiscal year ended December 29, 2023. Fiscal Year 2023 HighlightsCompleted Initial Public Offering in November 2023 Reported revenue of $633 million, which includes $434 million of Shimmick Projects revenue, an increase of 24% for fiscal year 2023 compared to fiscal year 2022 Diluted earnings per common share of $(0.11) Adjusted diluted earnings per common share of $0.48 Backlog of approximately $1.1 billion as of December 29, 2023, and reported an 18% increase in Shimmick Projects backlog for the fiscal year 2023 compared to fiscal year 2022 Secured key $200+ million...

Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato® Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024 Dosing commenced in VLS-01 (oral transmucosal DMT) Phase 1b study, with optimized formulation designed to improve pharmacokinetics and patient experience ahead of anticipated Phase 2 trial in TRD Cash, marketable securities, and committed term loan funding expected to fund operations into 2026NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage...

Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise PEMGARDA product availability in the U.S. anticipated imminently PEMGARDA is the first authorized mAb from Invivyd’s INVYMAB™ platform approach designed to address the challenge of rapid viral evolution Leveraged INVYMAB platform approach to design VYD2311, the company’s next anticipated SARS-CoV-2 candidate Cash and cash equivalents of $200.6 million as of December 31, 2023 In February 2024, the Company sold shares totaling $40.5 million in gross proceeds under its At-the-Market facility further strengthening its balance sheet ahead of PEMGARDA launchWALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE)...

Continuing to position the Company for success with a Strong Cash Balance, Reduced Operating Costs and Actively Managed and Diversified Stream Portfolio TORONTO, March 28, 2024 (GLOBE NEWSWIRE) — Carbon Streaming Corporation (Cboe CA: NETZ) (OTCQB: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company”) today reported its financial results for the fiscal year ended December 31, 2023. All figures are expressed in United States dollars, unless otherwise indicated. The Company will host a live audio call at 11:00 a.m. ET on Thursday, March 28, 2024. Carbon Streaming Founder and CEO Justin Cochrane stated: “In 2023, Carbon Streaming was able to improve its operating cash flow through the successful implementation of ongoing reductions in operating costs. As of December 2023, we have achieved savings of over $7.5 million for the fiscal...

MELVILLE, N.Y., March 28, 2024 (GLOBE NEWSWIRE) — Data Storage Corporation (Nasdaq: DTST) (“DSC” and the “Company”), a provider of diverse business continuity solutions for disaster-recovery, cloud infrastructure, cyber-security, and IT services, today provided a business update and reported financial results for the year ended December 31, 2023. Chuck Piluso, CEO of Data Storage Corporation, stated, “We are proud to report record revenue of $25.0 million for the 2023 fiscal year which we believe is a direct result of the strategic growth initiatives we implemented throughout the year. Through our innovative marketing programs and highly attended events, we had continued success in securing one time equipment sales, however, our primary emphasis has been on our recurring subscription based services, which increased 17% over the...

OTTAWA, March 28, 2024 (GLOBE NEWSWIRE) — Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three-month and one-year periods ended December 31, 2023. All amounts are in Canadian dollars and reported under International Financial Reporting Standards (IFRS) unless otherwise noted. “Telesat achieved a great deal in 2023 and I am pleased with our financial performance and, more importantly in terms of our future, the breakthrough we had in moving Telesat Lightspeed, our advanced Low Earth Orbit (LEO) satellite program, forward,” commented Dan Goldberg, Telesat’s President and CEO. “Our financial results reflect our continued disciplined execution, delivering Adjusted EBITDA1 above our 2023 guidance as well as industry-leading Adjusted EBITDA...

Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling program Completed patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025 $37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025 Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ETFOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) —  Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended December 31, 2023, and highlighted progress...